In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor

被引：4
|
作者：
Giocanti, N
Sadri, R
Legraverend, M
Ludwig, O
Bisagni, E
Leclerc, S
Meijer, L
Favaudon, V [1 ]
机构：
[1] Ctr Univ, Rech Labs 110 112, Inst Curie, INSERM,U350, F-91405 Orsay, France
[2] Ctr Univ, Inst Curie, CNRS, UMR 176, F-91405 Orsay, France
[3] CNRS, UPR 9042, Biol Stn, F-20682 Roscoff, France
来源：
ANTICANCER MOLECULES: STRUCTURE, FUNCTION, AND DESIGN | 1999年 / 886卷
关键词：
D O I：
10.1111/j.1749-6632.1999.tb09411.x
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：180 / 182
页数：3
相关论文
共 50 条
  • [1] Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors
    Legraverend, M
    Ludwig, O
    Bisagni, E
    Leclerc, S
    Meijer, L
    Giocanti, N
    Sadri, R
    Favaudon, V
    BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (07) : 1281 - 1293
  • [2] Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor
    Krystof, V
    McNae, IW
    Walkinshaw, MD
    Fischer, PM
    Müller, P
    Vojtesek, B
    Orság, M
    Havlícek, L
    Strnad, M
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2005, 62 (15) : 1763 - 1771
  • [3] Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor
    V. Kryštof
    I. W. McNae
    M. D. Walkinshaw
    P. M. Fischer
    P. Müller
    B. Vojtěšek
    M. Orság
    L. Havlíček
    M. Strnad
    Cellular and Molecular Life Sciences CMLS, 2005, 62 : 1763 - 1771
  • [4] A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors
    Gucky, Tomas
    Jorda, Radek
    Zatloukal, Marek
    Bazgier, Vaclav
    Berka, Karel
    Reznickova, Eva
    Beres, Tibor
    Strnad, Miroslav
    Krystof, Vladimir
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (15) : 6234 - 6247
  • [5] In vitro biotransformation of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine by mouse liver microsomes
    Rypka, M
    Vesely, J
    Chmela, Z
    Riegrová, D
    Cervenková, K
    Havlícek, L
    Lemr, K
    Hanus, J
    Cerny, B
    Lukes, J
    Michalíková, K
    XENOBIOTICA, 2002, 32 (11) : 1017 - 1031
  • [6] Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases
    Zatloukal, Marek
    Jorda, Radek
    Gucky, Tomas
    Reznickova, Eva
    Voller, Jiri
    Pospisil, Tomas
    Malinkova, Veronika
    Adamcova, Helena
    Krystof, Vladimir
    Strnad, Miroslav
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 61 : 61 - 72
  • [7] Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis
    Raynaud, FI
    Fischer, PM
    Nutley, BP
    Goddard, PM
    Lane, DP
    Workman, P
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (03) : 353 - 362
  • [8] In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice:: Glucosidation as the principal metabolic route
    Chmela, Z
    Vesely, J
    Lemr, K
    Rypka, M
    Hanus, J
    Havlícek, L
    Krystof, V
    Michnová, L
    Fuksová, K
    Lukes, J
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (03) : 326 - 334
  • [9] Cyclin-dependent kinase (CDK) inhibitors: development of a general strategy for the construction of 2,6,9-trisubstituted purine libraries. Part I
    Brun, V
    Legraverend, M
    Grierson, DS
    TETRAHEDRON LETTERS, 2001, 42 (46) : 8161 - 8164
  • [10] Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo
    McClue, Steven J.
    Stuart, Iain
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (03) : 561 - 570
12345